THX Pharma (ALTHX) is a listed biopharmaceutical company dedicated to discovering and developing treatments for rare neurological disorders. THX Pharma has two lead assets, TX01 and Batten-1:

TX01 is a proprietary, high-concentration oral solution built on an approved active ingredient, specifically formulated to address specific unmet needs in two rare lysosomal storage disorders: Niemann-Pick disease type C and Gaucher disease. THX Pharma (ALTHX) is currently finalizing its marketing authorization dossier for submission to both the EMA and FDA before year-end, with regional launches to follow across additional territories by 2027, and a projected revenue milestone of ~€50M by 2032. To accelerate patient access globally, the company has established two strategic licensing partnerships: Exeltis (Insud Pharma Group) holds exclusive commercialization rights across Europe, Latin America, and the MENA region, while Biocodex covers the United States and Canada. THX retains APAC rights and is actively seeking out-licensing partners to complete its global coverage.

Batten-1 is a proprietary, high-concentration oral liquid formulation of miglustat, optimized to meet the specific needs of pediatric and dysphagic patients with Batten disease — a devastating rare neurological disorder. Early clinical evidence is compelling: Phase I/II data demonstrated clear target engagement, reductions in neuronal death markers, and stabilization signals, while real-world data have shown clinically meaningful visual acuity stabilization. Both the FDA and EMA have endorsed a single pivotal Phase 3 pathway, streamlining the path to approval across major markets. THX Pharma (ALTHX) is currently advancing its Phase 3 program alongside an optimized Early Access strategy, underpinned by orphan designation and patent protection extending to ~2047 — providing a durable competitive moat. The global development and commercialization rights have been exclusively licensed to Biocodex, ensuring a well-resourced partner to drive the program through to launch and beyond. Peak revenue is modeled at ~€200M by 2033 across target markets.

Beyond its clinical-stage assets, THX Pharma can leverage a proprietary discovery platform to identify and develop next-generation drug candidates based on antisense oligonucleotide (ASO) technology. Two programs are currently underway:

The first targets TFEB, a transcription factor widely regarded as the master regulator of autophagy — the cellular recycling process by which cells clear damaged proteins and organelles. Dysregulation of autophagy is implicated in a broad spectrum of degenerative conditions, including Parkinson’s disease, Alzheimer’s disease, ALS, and Huntington’s disease, positioning TFEB modulation as a high-value therapeutic axis across neurology and beyond.

The second program is focused on characterizing an undisclosed target with promising therapeutic potential in glioblastoma — the most aggressive and lethal primary brain tumor in adults, with a median survival of under 15 months and fewer than 5% of patients alive at five years; approximately 300,000 new cases are diagnosed worldwide each year. Both programs are conducted in collaboration with leading French academic teams specializing in ASO therapeutics, and the TFEB project has received formal recognition through a France 2030 grant awarded by Bpifrance — validating both the scientific rationale and the quality of the research partnership.

NFL Biosciences is a Phase 3 French publicly listed biotech company (ticker: ALNFL), developing NFL-101 and NFL-102, disruptive drug candidates for smoking cessation with a new and distinctive mechanism of action.

NFL-101 has recently completed a randomized, double-blind, placebo-controlled, three-arm Phase 2b trial (two doses and placebo; n=318 patients) with a 12-month follow-up. The treatment involves two subcutaneous injections administered one week apart, optimizing both compliance and efficacy. NFL Biosciences has been able to show superiority of NFL-101 vs placebo, with an efficacy similar to Champix, the gold standard in smoking cessation therapy. Unlike Champix, NFL-101 shows no serious side effects and has a convenient dosing schedule.

NFL-102 is now entering a Phase 2b study.

To continue the development of NFL-101 beyond the Phase 2b CESTO-II clinical trial, and also NFL-102, the company would be keen to enter into discussions with potential new investors and pharmaceutical companies.

Igyxos is a French biotechnology company dedicated to addressing the growing global need for improved infertility solutions through novel therapeutics that make treatment more effective and efficient for men and women. Igyxos’ lead asset is IGX12, a first-in-class humanized monoclonal antibody which is Phase 2 ready.

Dolinnov develops a first-in-class non-opioid therapy for chronic pain, one of the largest unmet medical needs worldwide. Despite recent progress, current approaches targeting single ion channels (Nav1.7, Nav1.8) face key limitations due to redundancy, as other channels can compensate over time, limiting long-term efficacy.

Dolinnov addresses this challenge by targeting a novel and highly differentiated peripheral mechanism. Instead of blocking ion channels, Dolinnov modulates a key regulator of neuronal excitability using lipid-conjugated antisense oligonucleotide (L-ASO) technology to selectively target the dorsal root ganglion (DRG), where chronic pain originates.

This approach enables the reduction of pathological nerve activity while preserving normal sensory function. Dolinnov’s lead candidate, DOL-001, has demonstrated strong efficacy across multiple in vivo pain models, with a long-lasting effect and robust translational potential supported by human DRG expression and mechanistic data.

By targeting ion pumps rather than ion channels, Dolinnov offers a precise, peripheral, non-opioid alternative that avoids central nervous system toxicity and overcomes the limitations of current analgesics.

MABQI is a biotech company specializing in the discovery and development of next-generation innovative antibodies and immunotherapies.

Its LiteMab© Antibody Discovery Studio integrates a suite of synthetic fully human libraries with an AI-powered display platform. The innovative LiteMab Sense platform specializes in pH-sensitive binders, optimizing therapeutic safety and efficacy by activating selectively in tumor or acidic microenvironments.

MABQI is advancing a targeted oncology pipeline leveraging its LiteMab© platform, featuring first-in-class and best-in-class highly developable antibodies- some with pH-sensitive features—spanning antibody-drug conjugates (ADCs), multispecific antibodies, and T-cell engagers to address critical unmet needs in solid and hematological tumors.

MABQI also welcomes research collaborations with biopharma partners on antibody discovery and maturation programs.